PYPD
$4.56
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candi...
Recent News
When Will PolyPid Ltd. (NASDAQ:PYPD) Turn A Profit?
We feel now is a pretty good time to analyse PolyPid Ltd.'s ( NASDAQ:PYPD ) business as it appears the company may be...
PolyPid Ltd. Q4 2025 Earnings Call Summary
Moby summary of PolyPid Ltd.'s Q4 2025 earnings call
PolyPid Ltd (PYPD) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges
PolyPid Ltd (PYPD) reports significant progress in clinical trials and strategic partnerships, despite facing increased expenses and net losses.
PolyPid (PYPD) Q4 2025 Earnings Call Transcript
Yehuda Leibler: Thank you, operator, and thank you all for joining PolyPid's Fourth Quarter and Full Year 2025 Earnings Conference Call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid's Chief Financial Officer; and Ori Warshavsky, Chief Operating Officer, U.S. of PolyPid. Earlier today, PolyPid released its financial results for the 3 and 12 months ending December 31, 2025.
PolyPid Q4 Earnings Call Highlights
PolyPid (NASDAQ:PYPD) said 2025 marked a “pivotal year” as the company completed its SHIELD II Phase 3 trial and moved D-PLEX100 into the final stages of regulatory preparation, while also advancing U.S. commercial partnership discussions ahead of a planned new drug application submission in early 2